BLU 285

Drug Profile

BLU 285

Alternative Names: BLU-285

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Blueprint Medicines
  • Class Antineoplastics; Skin disorder therapies; Small molecules
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic mastocytosis; Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal stromal tumours; Solid tumours; Systemic mastocytosis

Most Recent Events

  • 10 Nov 2017 Updated efficacy and adverse events data from a phase I trial in Gastrointestinal stomal tumours released by Blueprint Medicines
  • 05 Jun 2017 Blueprint Medicines plans a global, randomised, pivotal phase III trial for Gastrointestinal stomal tumours (Second-line therapy or greater) in the first half of 2018
  • 05 Jun 2017 BLU 285 receives Breakthrough Therapy status for Gastrointestinal stromal tumours (Inoperable/Unresectable, Metastatic disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top